April 02, 2026

CDC Lists Dozens of Infectious Disease Tests as Unavailable

More than two dozen assays paused or discontinued, with alternative testing options noted

Conexiant

April 01, 2026

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

Conexiant

April 01, 2026

FDA Broadens CFTR Therapy Eligibility

The FDA expanded use of CFTR modulators to include more CF gene variants, increasing treatment eligibility across a wider US patient population.

Conexiant

March 30, 2026

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

Conexiant

March 27, 2026

FDA Drops Age Limit for Neffy

Needle-free epinephrine expands access for younger children meeting weight criteria

Conexiant

March 26, 2026

St. Louis Pediatrician Gets 20-Year Sentence

A physician exploited patients with addiction for nearly a decade, trading prescriptions for sex acts, photos, and cash

Conexiant

March 19, 2026

Sleep Apnea Device Receives FDA Approval

Randomized trial data support the approval, with sustained improvements in apnea severity observed.

Conexiant

March 17, 2026

Obesity Medications Get New Guidance

Panel outlines pharmacotherapy roles across obesity complications and long-term weight management.

Conexiant

March 17, 2026

Flu Vaccine Cut Hospitalizations Despite Drifted H3N2 Strain

Interim CDC estimates found the 2025–2026 vaccine reduced outpatient influenza visits by up to 41% and hospitalizations by up to 41%.

Conexiant

March 13, 2026

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.

Conexiant